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Fibrocytes are bone marrow hematopoietic-derived cells that also express a mesenchymal
cell marker (commonly collagen I) and participate in fibrotic diseases of multiple organs.
Given their origin, they or their precursors must be circulating cells before recruitment
into target tissues. While most previous studies focused on circulating fibrocytes, here
we focus on the fibrocyte phenotype in fibrotic tissue. The study’s relevance to human
disease is heightened by use of a model in which bleomycin is delivered systemically,
recapitulating several features of human scleroderma including multi-organ fibrosis not
observed when bleomycin is delivered directly into the lungs. Using flow cytometry, we
find in the fibrotic lung a large population of CD45high fibrocytes (called Region I) rarely
found in vehicle-treated control mice. A second population of CD45+ fibrocytes (called
Region II) is observed in both control and fibrotic lung. The level of CD45 in circulating
fibrocytes is far lower than in either Region I or II lung fibrocytes. The chemokine
receptors CXCR4 and CCR5 are expressed at higher levels in Region I than in Region
II and are present at very low levels in all other lung cells including CD45+/collagen
I- leucocytes. The collagen chaperone HSP47 is present at similar high levels in both
Regions I and II, but at a higher level in fibrotic lung than in control lung. There is also
a major population of HSP47high/CD45- cells in fibrotic lung not present in control lung.
CD44 is present at higher levels in Region I than in Region II and at much lower levels
in all other cells including CD45+/collagen I- leucocytes. When lung fibrosis is inhibited
by restoring caveolin-1 activity using a caveolin-1 scaffolding domain peptide (CSD), a
strong correlation is observed between fibrocyte number and fibrosis score. In summary,
the distinctive phenotype of fibrotic lung fibrocytes suggests that fibrocyte differentiation
occurs primarily within the target organ.
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INTRODUCTION
Fibrocytes are defined as bone marrow hematopoietic-derived
cells that appear to be transitional in that they express leukocyte
markers such as CD45 plus mesenchymal cell markers such
as collagen I (Keeley et al., 2009; Pilling et al., 2009; Herzog
and Bucala, 2010). Fibrocytes are present at high levels in the
target tissue(s) in a variety of fibrotic diseases including sclero-
derma (systemic sclerosis, SSc) (Phillips et al., 2004; Falk, 2006;
Haudek et al., 2006; Kisseleva et al., 2006; Wang et al., 2008;
Mehrad et al., 2009; Niedermeier et al., 2009; Vakil et al., 2009;
Mathai et al., 2010; Murray et al., 2011; Nikam et al., 2011).
Given their origin in the bone marrow, it is clear that fibro-
cytes must traffic through the circulation to be recruited to
target tissues through the action of chemokines on fibrocyte cell
surface receptors. Once fibrocytes enter the target tissue, they
participate in the progression of fibrosis by differentiating into
fibroblasts and/or by secreting cytokines that activate resident
fibroblasts.
Most previous studies on fibrocytes have been performed
using human blood because of the ease in obtaining this material
from control subjects and patients with a variety of different dis-
eases. For example, a high level of circulating fibrocytes is an indi-
cator of poor prognosis in patients with idiopathic pulmonary
fibrosis (IPF) (Moeller et al., 2009). Very few studies have been
performed on the quantification and phenotype of fibrocytes in
target tissues such as the lung. Despite the focus in the liter-
ature on circulating fibrocytes, it appears that there are many
more fibrocytes in the fibrotic lung than in the circulation
(Phillips et al., 2004; Ishida et al., 2007). Moreover, little work has
been done on the phenotypic characterization of lung fibrocytes
beyond their expression of CD45, collagen I, and the chemokine
receptor CXCR4. This is particularly noteworthy because while
it has been pointed out that there appear to be too few circulat-
ing fibrocytes to account for the large number of fibrocytes in the
fibrotic lung (Phillips et al., 2004), the possibility has not been
examined that this may occur because fibrocyte differentiation
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is occurring primarily in the lungs (or in other fibrotic target
organs).
Two recent technical advances have been instrumental in
allowing us to perform studies on the quantification and
phenotyping of lung fibrocytes. The most common approach
to inducing lung fibrosis in mice is to deliver bleomycin
directly into the lungs, usually by intratracheal administration.
However, we recently observed that systemic administration of
bleomycin using osmotic minipumps produces a disease that
more closely resembles human SSc than does direct adminis-
tration of bleomycin into the lungs (Lee et al., 2014). Features
that are common to the Pump Model and SSc, but not to the
Direct Model, include: (1) Fibrosis is limited to the subpleural
portion of the lung; (2) Inflammation is relatively limited; (3)
Hypertrophic type II alveolar epithelial cells are present at high
levels; and (4) Lung fibrosis is accompanied by dermal fibro-
sis and fibrosis of other internal organs. A second issue that we
have addressed is that previous studies on fibrocytes have shown
that it is difficult to determine clearly by flow cytometry which
CD45+ cells are also collagen I+. This distinction is difficult
because, in reality, collagen I expression levels are not categori-
cal (i.e., negative or positive), but rather a continuum of collagen
I expression levels exists. In addition, because most anti-collagen
I antibodies used in flow cytometry are rabbit polyclonal anti-
bodies, the isotype control is non-immune rabbit IgG which can
vary in degree of non-specific labeling, possibly due to the intrin-
sic heterogeneity of the preparations. We have addressed this
problem by making a polyclonal antibody against a polypeptide
from the human collagen Iα1 C-terminal propeptide. Using this
antibody, we can ensure that we are labeling cells that express
collagen Iα1 rather than cells that bind mature collagen (lacking
this propeptide) and we can distinguish specific antibody binding
from non-specific binding by using the immunogenic peptide in
competition experiments.
In the current study, a comparison by flow cytometry of the
number and phenotype of lung fibrocytes in mice treated with
bleomycin or saline vehicle utilizing our PumpModel has allowed
us to make several striking, novel observations regarding the
levels of CD45, collagen I, CD14, CD34, CXCR4, CCR5, HSP47,
and CD44 in lung fibrocytes and to demonstrate that there is a
high correlation between fibrocyte number and fibrosis severity
in fibrotic lung tissue. These observations suggest that fibrocyte
differentiation occurs primarily in the lung and that treatments
that target fibrocyte recruitment and differentiation [in particu-
lar administration of the caveolin-1 scaffolding domain peptide
(CSD)] are likely to be effective treatments for fibrotic diseases of
the lung and other organs.
MATERIALS AND METHODS
BLEOMYCIN TREATMENT OF MICE AND HARVESTING OF TISSUE
The following procedures were approved by the MUSC
Institutional Animal Care & Use Committee. Ten-week old, male
CD1 mice (Charles River Laboratories, Boston, MA) were main-
tained under pathogen-free conditions. Osmotic minipumps
(ALZET 1007D; DURECT Corporation, Cupertino, CA) contain-
ing either 100μl saline vehicle or bleomycin (100 U/kg) designed
to deliver their contents at 0.5μl/h for 7 days were implanted
under isofluorane anesthesia under the loose skin on the back of
the mice slightly caudal to the scapulae. Pumps were removed on
day 10–12.
In the experiment shown in Figure 10, at the same time that
the pump containing bleomycin or saline was removed, a second
pump (ALZET 2002, designed to deliver its contents of 200μl at
0.5μl/h for 14 days) was inserted containing CSD peptide (5mg
per ml in 10% DMSO in water) or vehicle.
Mice were sacrificed on the indicated day. Under deep anes-
thesia, the rib cage was opened to expose the lungs. Mice were
systemically perfused via the left ventricle with PBS. The left
lung was then tied off and removed for flow cytometry exper-
iments. The remaining right lung was further perfused with
buffered zinc formalin fixative (Z-Fix, Anatech, Battle Creek, MI).
Fixed lung tissue was then removed and embedded in paraffin.
Table 1 | Antibodies used in flow cytometry experiments.
Specificity (description) Label Product # Concentration
CD45 (rat anti-mouse, clone 30-F11) PE-Cy7 BD 552848 0.50μg/ml
Collagen Iα1 C-terminal propeptide “Pro” (rabbit anti-human, polyclonal) None 1.67μg/ml
CD14 (rat anti-mouse, clone rmC5-3) APC BD 560634 0.75μg/ml
CD34 (rat anti-mouse, clone RAM34) AF647 BD 560230 1.50μg/ml
Collagen I N-terminal propeptide (rat anti-human, clone M-58) None EMDMillipore MAB1912 1.00μg/ml
Collagen I C-terminal propeptide (mouse anti-human, clone PCIDG10) None EMDMillipore MAB1913 1.00μg/ml
Collagen I (rabbit anti-human/bovine, polyclonal) AF647* Rockland 600-401-103 1.00μg/ml
CXCR4 (rat anti-mouse, clone 2B11) APC eBioscience 17-9991-82 1.00μg/ml
CCR5 (Armenian Hamster anti-mouse, clone HM-CCR5) APC BioLegend 107012 1.50μg/ml
HSP47 (mouse anti-rat, clone M16.10A1) AF647* Enzo ADI-SPA-70 1.00μg/ml
CD44 (rat anti-mouse, clone IM7) APC BD 559250 0.50μg/ml
CD16/CD32 “Fc Block” (rat anti-mouse, clone 2.4G2) None BD 553142 1μg/1 × 106 cells
Goat anti-rabbit secondary AF488 Life technologies A11034 2.00μg/ml
Goat anti-mouse secondary AF647 Life technologies A21235 2.00μg/ml
Goat anti-rat secondary AF647 Life technologies A21247 2.00μg/ml
*Labeled using an Alexa Fluor 647 Protein Labeling Kit (Invitrogen, Carlsbad, CA, A-20173) as described by the manufacturer. AF, Alexa Fluor.
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FIGURE 1 | Characterization of Pro byWestern Blot and use in flow
cytometry. (A)Human lung fibroblast culture supernatant wasWestern blotted
using Pro (0.2μg/ml) competed with Non-specific peptide (immunogenic
peptide for Telo, 0.4μg/ml = 142-fold molar excess), with Specific peptide
(immunogenic peptide for Pro, 0.4μg/ml = 142-fold molar excess), or with
serial 5-fold dilutions of Specific peptide. The prominent polypeptide detected
is full-length 180 kD procollagen Iα1. The minor, slightly smaller polypeptide
lacks the N-terminal propeptide. (B) Total lung cells from a bleomycin-treated
mouse sacrificed 28 days after initiation of treatment were immunolabeled for
CD45 and, as indicated, with no additional antibody, with Pro competed with
specific peptide (142-fold molar excess), and with Pro competed with
non-specific peptide (142-fold molar excess). Scatter plots are presented with
CD45 fluorescence intensity on the y-axis and Pro (or unlabeled) fluorescence
intensity on the x -axis. (C) Total lung cells from a saline-treated mouse and a
bleomycin-treated mouse sacrificed 28 days after initiation of treatment were
immunolabeled for CD45 and Pro. Scatter plots are presented with CD45
fluorescence intensity on the y-axis and Pro fluorescence intensity on the
x-axis. The zones named Regions I–IV are shown and are used throughout this
study. (D)CD45 or Pro levels in Regions I–IV, and I+ II are shown in terms of the
average ± s.e.m. of the median fluorescence intensity of each of 18 saline and
26 bleomycin mice sacrificed 28 days after initiation of treatment. S, saline; B,
bleomycin. Error bars are not shown and the t-test was not applied to these
data because CD45 and Pro fluorescence intensity were the criteria used to
define Regions I–IV.
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Sections (4μm) were stained with hematoxylin and eosin (H&E)
or Masson’s Trichrome.
FLOW CYTOMETRY
Lung tissue prepared as described above were washed in cold
DMEM and minced into small pieces using fine surgical scissors.
The tissue from each mouse was resuspended in 5ml of colla-
genase (1mg/ml, Roche #10103578001) and shaken at low speed
for 45min at 37◦C. Digestion was stopped by addition of 10ml of
FIGURE 2 | Specificity of Pro and Telo by Western Blotting of tissue
extracts. A soluble tissue extract of shaved mouse skin was prepared
using detergent-free neutral buffer as previously described for lung tissue
(Lee et al., 2014). Following centrifugation, the pellet was re-extracted by
boiling for 3min in SDS-PAGE sample buffer. Aliquots of the soluble extract
(Sol) and the pellet extract (Plt) representing equal amounts of tissue were
then resolved by SDS-PAGE and Western blotted using Pro and Telo as
indicated. The identity of the various forms of collagen I recognized by
these antibodies is described in the text and indicated on this figure.
DMEM/10% FBS. The sample was passed through a 40μm cell
strainer to prepare amonodisperse cell suspension. Cells were col-
lected by centrifugation (1200 rpm, 10min, 4◦C, Beckman GS-6R
centrifuge) and the cell pellets resuspended in 1ml ACK lysing
buffer (LONZA #10-548E) for 5min to remove red blood cells.
Lung cells, approximately ten million per mouse, were then col-
lected by centrifugation, washed with PBS, collected, and fixed
and permeabilized for 20min at 4◦C in 1ml Cytofix/Cytoperm
(BD #554722). Finally, cells were washed in FACS buffer (BD
Perm/Wash Buffer 554723) and resuspended at 4 × 106 per ml
in FACS buffer/Fc Block (BD, 1μg per 1 × 106 cells).
Antibodies used in immunolabeling are summarized in
Table 1. All incubations with antibody were 30min at 4◦C on a
rocker at low speed, all washes were done with FACS buffer, all
resuspensions were with FACS buffer/Fc Block. Prior to use, the
antibodies designated Pro or Telo were preincubated with specific
or non-specific peptide (30min, RT, 10μg per ml IgG in FACS
buffer plus 20μg per ml peptide). (Peptides had been reduced
and alkylated as described below). The antibody/peptide mix-
ture (50μl) was then incubated with 0.25ml lung cells. Following
washing, the cells were second incubated with anti-rabbit sec-
ondary antibody. Following washing, the cells were simultane-
ously third incubated with directly-labeled anti-CD45 and with
directly-labeled antibodies against either CD14, CD34, Rockland
anti-collagen I, CXCR4, CCR5, HSP47, or CD44. Following wash-
ing, the immunolabeled cell suspension was analyzed by FACS
using a MoFlo Astrios (Beckman Coulter). At least 20,000 events
were recorded per sample.
In experiments which involved immunolabeling CD45, Pro,
and MAB1912 or MAB1913, because MAB1912 and MAB1913
were not available directly labeled and could not be directly
labeled in our laboratory, it was necessary to simultane-
ously first label with Pro and MAB1912 or MAB1913, then
to simultaneously second label with appropriate secondary
antibodies. As above, in a third incubation the cells received
directly-labeled anti-CD45.
FIGURE 3 | Time course of cell numbers in Regions I and II. The percent
of total lung cells in Region I (A) or II (B) in saline- or bleomycin-treated mice
3, 10, or 28 days after initiation of treatment is shown. Sal, saline; Bleo,
bleomycin. These data represent the average ± s.e.m. for the following
number of mice in each category: 3-day saline, 3; 3-day bleomycin, 3; 10-day
saline, 3; 10-day bleomycin, 3; 28-day saline, 18; 28-day bleomycin, 26.
Because there was no difference between the percent of cells in Region II in
saline and bleomycin lung at day 3 and at day 10, saline and bleomycin data
were pooled before determining the statistical significance in the decrease in
percent of cells in Region II between day 3 and 10. ∗∗p < 0.01, ∗∗∗p < 0.002.
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FIGURE 4 | CD14 and CD34 in Regions I–IV. (A) Total lung cells from a
bleomycin-treated mouse sacrificed 28 days after initiation of treatment were
immunolabeled for Pro and either CD14 or CD34. Scatter plots of fluorescence
intensity are presented with CD14 or CD34 on the y-axis and Pro on the x-axis.
Note that unlike CD45 (see Figure 1), neither CD14 nor CD34 had a clearcut
bimodal distribution of fluorescence intensity. (B) Total lung cells from a
saline- and a bleomycin-treated mouse sacrificed 28 days after initiation of
treatment were immunolabeled for CD45, Pro, and either CD14 or CD34. Cells
from the indicated Regions (the indication under CD34 applies to CD14 as
well) from CD45-Pro scatter plots were selected and the fluorescence
intensity of CD14 or CD34 in these cells plotted vs. cell count. The bar at
1 × 102 marks the maximum value of fluorescence intensity (99th percentile)
detected in unlabeled cells. The different cell count scales for each Region are
indicated. Similar results were observed in three independent experiments.
In experiments on circulating fibrocytes, blood (typically
about 1ml) was collected by heart stick into a tube already con-
taining heparin (500USP units) as anti-coagulant. PBMC were
isolated by routine methods and immunolabeled as described
above.
COLLAGEN PEPTIDE ANTIBODIES
19-amino acid peptides from the human collagen Iα1 C-terminal
propeptide and C-terminal telopeptide were synthesized with an
additional Cys residue at the N-terminus. This residue was used
to link the peptides to KLH for immunization of rabbits and
to Sulfolink beads (Thermo Fisher Scientific Inc., Rockford, IL).
Total IgG was purified from rabbit serum. Specific IgG was then
affinity purified from total IgG using the immunogenic peptides
attached to Sulfolink beads. After elution, affinity-purified IgG
was spin-concentrated and desalted into PBS.
REDUCTION/ALKYLATION OF PEPTIDES
10mg of the immunogenic peptide for Pro and for Telo was
dissolved in 1ml TE (50mM Tris, pH 8.5/5mM EDTA). Next,
50μl of 1M DTT in TE was added and incubated 30min, 37◦C.
Following clarification of the solution, the peptides were alky-
lated by addition of 225μl of 0.67M iodoacetimide in TE and
incubation for 30min, 37◦C. Finally the peptides were desalted
by gel filtration in PBS on a 10-ml Sephadex G-15 column. Peak
fractions were pooled and mixed with an equal volume of 100%
glycerol for storage in solution at −20◦C.
FIBROSIS SCORES
Fibrosis was quantified by light microscopic evaluation of tis-
sue sections. Briefly, for each mouse a Masson’s Trichrome-
stained slide and an H & E-stained slide were scored blind using
an arbitrary scale in which normal morphology = 0; almost
normal = 1; slightly altered morphology = 2; moderately altered
morphology = 3; and severely altered morphology = 4. After the
blinding code was broken, the final score for each mouse was
determined by adding its Masson’s Trichrome score to its H & E
score.
EGFP MICE
Ten to 14-week-old male C57BL6/Ly5.1 mice were prepared for
bone marrow transplantation using a single dose (9.0 Gy) of
total body irradiation. Ten to 12-week-old female EGFP/Ly5.2
mice were used as donors (Visconti et al., 2006). Briefly, donor
mice were humanely sacrificed by CO2 inhalation. Bone marrow
cells were flushed from femurs and tibiae and washed in Ca++-
and Mg++-free phosphate-buffered saline containing 0.1% BSA.
A monodisperse suspension was prepared by gentle trituration
and filtering through a 40-μ m filter. Mononuclear cells were
isolated by density gradient centrifugation using Lympholyte-M
(Cedarlane Labs, Burlingame, NC). 2.0 × 105 of these EGFP+
donor bone marrow cells were transplanted into the irradi-
ated recipients by tail vein injection. As previously described
(Visconti et al., 2006), peripheral blood chimerism was assayed
at 30 days post-transplantation and multi-lineage hematopoietic
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FIGURE 5 | Comparison of Pro to other collagen antibodies. Total lung
cells from a bleomycin-treated mouse sacrificed 28 days after initiation of
treatment were immunolabeled for CD45, Pro, and one of MAB1913,
MAB1912, or Rockland. In the upper left panel, a scatter plot is shown with
CD45 on the y-axis, Pro-on the x-axis, and a box containing Regions I and II
with the cells inside the box selected and marked in green. In the other three
panels, scatter plots are shown with CD45 on the y-axis and, as indicated,
MAB1913, MAB1912, or Rockland on the x-axis. The same cells marked green
due to their position on CD45-Pro scatter plots are green on these plots. Note
that the green cells are in the same position on all panels indicating that the
same cells are recognized by Pro, MAB1913, MAB1912, and Rockland. In
contrast to the similarity in all four panels among CD45+ cells, note that, as
described in the text, differences are seen in the position of CD45- cells.
Similar results were observed in three independent experiments.
reconstitution was assayed at 60 days. Mice exhibiting high levels
of reconstitution were used in subsequent studies.
STATISTICAL ANALYSES
All numerical data are expressed as average ± standard error of
the mean (s.e.m.) and were analyzed using Student’s t-test to eval-
uate statistical significance. In all figures, statistical significance is
expressed as ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.002.
RESULTS
IDENTIFICATION OF CD45HIGH/PRO+ CELLS FOUND ONLY IN
BLEOMYCIN LUNG
Rabbit polyclonal antibodies against the human collagen Iα1
C-terminal propeptide and C-terminal telopeptide were prepared
as described in the Methods. We refer to the propeptide antibody
as Pro and to the telopeptide antibody as Telo. In this paper we
only show flow cytometry data obtained with Pro, although sim-
ilar data were obtained with Telo. To characterize Pro, we first
demonstrated by Western blotting that its activity can be almost
completely blocked in a dose-dependent manner by its specific
immunogenic peptide, but not by the non-specific immunogenic
peptide for Telo (Figure 1A).
To further characterize Pro and Telo, the ability of these
antibodies to detect collagen I on Western blots of mouse tis-
sue extracts was determined. Skin was used for these experi-
ments because it contains a higher level of collagen I than does
lung. Skin was homogenized sequentially with neutral buffer
(to extract soluble collagen I that had not yet been incorpo-
rated into the extracellularmatrix) followed by SDS-PAGE sample
buffer extraction of the pellet (to extract collagen I that had
begun to be cross-linked into the extracellular matrix, but was
not fully insoluble). As expected (Figure 2), Pro detected full-
length 180 kD procollagen I and the slightly smaller pC (pro-
collagen I lacking the N-terminal propeptide) in the soluble
fraction but did not recognize any form of collagen I present in
the pellet fraction because propeptides are removed from col-
lagen I prior to its incorporation into the extracellular matrix.
In sharp contrast (Figure 2) and as expected, Telo recognized
primarily 140 kD mature (i.e., lacking propeptides) collagen I
monomers and some dimers in the soluble fraction but recog-
nized a higher level of collagen I in the pellet fraction, most
of which was covalently crosslinked into dimers, trimers, and
tetramers. While 180 kD procollagen I and pC are not shown
to be detected by Telo in Figure 2, they are observed on longer
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FIGURE 6 | Chemokines CXCR4 and CCR5 in Regions I–IV. (A)Total lung
cells from saline- and bleomycin-treated mice sacrificed 28 days after
initiation of treatment were immunolabeled for CD45, Pro, and either
CXCR4 or CCR5. CXCR4 or CCR5 levels in Regions I–IV, and I + II are
shown in terms of the average ± s.e.m. of the median fluorescence
intensity of each of the following number of mice: CXCR4, 15 saline and 18
bleomycin; CCR5, 9 saline and 12 bleomycin. S, saline; B, bleomycin. (B)
The 2% of the total lung cells with the highest levels of CXCR4 or CCR5
were selected and marked green. Scatter plots of CD45 on the y-axis vs.
Pro on the x-axis showing these selected, green marked cells are
presented. As noted in the text, the position of the green-marked cells is
different for CXCR4 and CCR5. Similar results were observed in three
independent experiments. ∗p < 0.05, ∗∗∗p < 0.002.
exposures of the same Western blot. In summary, Figure 2
demonstrates that procollagen I is almost completely in the sol-
uble fraction and that the great majority of collagen I in tissue
is the mature molecule or multimers of the mature molecule
and is present in the pellet fraction. Figure 2 further demon-
strates that Pro and Telo have the expected, distinct specificities
and do not appear to recognize any proteins other than forms of
collagen I.
We next performed a competition experiment by flow cytom-
etry. Total lung cells from a mouse treated with bleomycin
using the Pump Model (Lee et al., 2014) and sacrificed at day
28 were double-labeled for CD45 and Pro with competition
with either the Pro or Telo immunogenic peptides (Figure 1B).
Specific competition showed no CD45+ cells with a fluores-
cence intensity > 9 × 102 although with non-specific competi-
tion there was a large population of CD45+/Pro+ cells using
this cutoff. Experiments with cells immunolabeled only for CD45
confirmed that 9 × 102 is an appropriate cutoff for specific label-
ing. Having established criteria for Pro+ labeling, we compared
total lung cells from Pump Model mice treated with bleomycin
or with saline vehicle (Figure 1C). Examination of data from
18 saline-treated and 26 bleomycin-treated mice has allowed us
to divide CD45/Pro scatter plots into four Regions: Region I,
CD45high/Pro+ (CD45high = fluorescence intensity > 8 × 103);
Region II, CD45+/Pro+ (CD45+ = fluorescence intensity> 5 ×
102); Region III, CD45+/Pro-; and Region IV, CD45-. Strikingly,
a significant number of cells are present in Region I only in mice
treated with bleomycin. The median fluorescence intensity for
CD45 and Pro in Regions I–IV from saline and bleomycin mice
(Figure 1D) is in accord with the position of these Regions in the
scatter plots in Figure 1C.
When the time course of accumulation of cells in Regions I
and II was examined (Figure 3), in Region I the number of cells
in mice receiving Saline vehicle was always low while the number
in bleomycin-treated mice rose dramatically from day 3 to days
10–28. Interestingly, although the percentage of cells in Region
II in naïve mice was no more than 4% (not shown), this num-
ber increased to over 10% in both saline and bleomycin-treated
mice 3 days after pump implantation before returning to almost
baseline level at 10 days, indicating that the increase at 3 days is
due to pump implantation and not the contents of the pump.
At 28 days, the level in saline mice remained at the 10-day level,
while the level in bleomycin mice increased slightly and was sta-
tistically significantly different from the level in saline mice. In
summary, these studies show that there is always a population
of CD45+Pro+ (Region II) cells in mouse lung, but there is a
rather large population of CD45high/Pro+ (Region I) cells that
are only present in bleomycin-treated mice and that take time to
accumulate.
To confirm the identity of Region I and Region II cells as
bone marrow-derived cells, similar experiments were performed
in mice reconstituted with bone marrow expressing EGFP (not
shown). In both saline- and bleomycin-treated mice, consistent
with their expression of the hematopoietic cell marker CD45, cells
in Regions I–III were 100% EGFP+, while cells in Region IV were
only about 10% EGFP+.
CD14 AND CD34
Various authors have considered the status of CD14 and CD34
expression to be important in the characterization of circulat-
ing fibrocytes. Therefore, we performed experiments in which
total lung cells from saline- and bleomycin-treated mice sacri-
ficed 28 days after treatment were immunolabeled for CD45, Pro,
and either CD14 or CD34 (Figure 4). Unlike CD45 in which a
bimodal immunolabeling distribution is obvious in both saline
and bleomycin lung (Figure 1C), neither CD14 nor CD34 show a
bimodal distribution (Figure 4A). CD14 and CD34 levels in cells
from Regions I–IV of saline- and bleomycin-treated mice were
also compared (Figure 4B). Data for Regions I and II were pooled
because there was no difference between these regions. For CD14,
essentially no cells in Region III were positive, while a similar per-
centage of cells in both saline- and bleomycin-treated mice were
positive in Regions I + II (17.5%). For CD34, again essentially no
cells in Region III were positive. In contrast to CD14, the percent-
age of CD34+ cells was higher in bleomycin lung than in saline
lung in Regions I + II (69 vs. 40%).
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COMPARISON OF PRO WITH OTHER COLLAGEN I ANTIBODIES
To validate our Pro antibody and to compare cells recognized by
various collagen I antibodies, we performed experiments in which
total lung cells from bleomycin-treated mice sacrificed 28 days
after treatment were immunolabeled for CD45, Pro, and one of
EMD Millipore MAB1913 (Mouse monoclonal anti-human col-
lagen Iα1 C-terminal propeptide), EMDMilliporeMAB1912 (Rat
monoclonal anti-human collagen Iα1 N-terminal propeptide), or
Rockland Rabbit polyclonal anti-human and bovine collagen I
(this is the most frequently used antibody for detecting fibrocytes
by flow cytometry, particularly in experiments using mouse
samples). The indicated cells from Regions I and II in a scatter
plot of CD45 vs. Pro were marked green and then these same cells
were localized in scatter plots of CD45 vs. MAB1913, MAB1912,
and Rockland (Figure 5). In every case the green marked cells
exhibited a similar distribution on the scatter plot indicating
that this population of CD45+ cells is also recognized by each
of these four anti-collagen antibodies. In contrast, these four
antibodies differed in their ability to recognize CD45- cells. The
most Pro+ CD45- cells had a similar fluorescence intensity to the
green marked cells, the most MAB1913+ CD45- cells had less
fluorescence than the green marked cells, the most Rockland+
CD45- cells had more fluorescence than the green marked cells,
and the most MAB1912+ CD45- cells had far more fluores-
cence than the green marked cells (Figure 5). Whether these
differences result from the recognized epitopes being differen-
tially expressed or being differentially available due to distinctive
patterns of subcellular localization, masking, or presence on dif-
ferent molecular forms of collagen I (e.g., fragments or fibrils)
is an open question. It is also noteworthy that we have obtained
positive results using MAB1912 and MAB1913 on mouse sam-
ples by flow cytometry and by immunohistochemistry (submitted
for publication) because these antibodies were previously thought
not to recognize mouse collagen I.
CHEMOKINE RECEPTORS CXCR4 AND CCR5
In order for fibrocytes to play a role in fibrosis, it is necessary for
them or their progenitors to be recruited into target tissues. In
this process chemokines secreted by cells in target tissues promote
recruitment into the tissue by binding to specific receptors on
circulating cells. Two of the most prominent of these chemokine
receptors are CXCR4 and CCR5. In these experiments, total lung
cells from saline- and bleomycin-treated mice sacrificed 28 days
after treatment were immunolabeled for CD45, Pro, and either
CXCR4 or CCR5. For both CXCR4 and CCR5, the level of flu-
orescence intensity was high in Regions I and II, while Regions
III and IV were unlabeled or at most barely positive (Figure 6A).
For example, for both CXCR4 and CCR5, the median fluores-
cence intensity in bleomycin Region I was > 10-fold higher than
in bleomycin Regions III or IV. For both CXCR4 and CCR5,
there was a significant difference in the fluorescence intensity
between bleomycin Region I and bleomycin Region II. While the
fluorescence intensity level for CXCR4 is significantly higher in
bleomycin Regions I and I + II compared respectively to Saline
Regions I and I + II, it is not for CCR5. It is also quite noteworthy
that the cells that have the highest levels of CXCR4 are not the
same cells that have the highest levels of CCR5 (Figure 6B). The
green marked cells with the highest level of CXCR4 are skewed
toward the highest levels of CD45 and Pro, while the green
marked cells with the highest level of CCR5 are skewed toward
the arbitrary border between Region III and Regions I and II and
in many cases are slightly across the border.
COLLAGEN CHAPERONE HSP47
HSP47 is upregulated in a high percentage of the cells in
fibrotic mouse and human lung tissue (Lee et al., 2014) and
thus serves as a cell-associated, surrogate marker for collagen
expression. In these experiments, total lung cells from saline- and
bleomycin-treated mice sacrificed 28 days after treatment were
FIGURE 7 | Collagen Chaperone HSP47 in Regions I–IV. (A) Total lung cells
from saline- and bleomycin-treated mice sacrificed 28 days after initiation of
treatment were immunolabeled for CD45, Pro, and HSP47. HSP47 levels in
Regions I–IV, and I + II are shown in terms of the average ± s.e.m. of the
median fluorescence intensity of each of 11 saline and 17 bleomycin mice. S,
saline; B, bleomycin. (B) In some of the experiments that make up (A), cells
from the indicated Regions from CD45-Pro scatter plots were selected and
the fluorescence intensity of HSP47 in these cells plotted vs. cell count. The
bar at 1 × 102 marks the maximum value of fluorescence intensity (99th
percentile) detected in unlabeled cells. The different cell count scales for each
Region are indicated. Note the large number of cells in bleomycin Region IV
with a fluorescence intensity > 1 × 103, a level not observed in any other
region. Similar results were obtained in four independent experiments.
∗∗p < 0.01, ∗∗∗p < 0.002.
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immunolabeled for CD45, Pro, and HSP47 (Figure 7). Unlike
CXCR4 and CCR5, only Region III showed little, if any, HSP47
immunolabeling. Regions I, II, I + II, and IV all showed a
higher level of immunolabeling in bleomycin-treated mice than
in saline-treated mice (Figure 7A). In particular, a major sub-
population of bleomycin Region IV (i.e., CD45- cells) with a
fluorescence intensity > 1 × 103 (Figure 7B) is observed that is
not present in bleomycin Region I + II or in saline Region IV.
Cells with this high fluorescence intensity represent 4.5% of the
cells in bleomycin Region IV, but only 1.5% of the cells in saline
Region IV (p = 0.03). Also unlike CXCR4 and CCR5, there was
not a statistically significant difference between bleomycin Region
I and bleomycin Region II.
CD44
Because CD44 is considered to be an important functional marker
on mesenchymal stem cells, we determined whether CD44 might
also be present on fibrocytes. In these experiments, total lung cells
from saline- and bleomycin-treated mice sacrificed 28 days after
initiation of treatment were immunolabeled for CD45, Pro, and
CD44 (Figure 8). While no statistically significant difference was
observed for any Region between saline- and bleomycin-treated
mice, huge differences were observed between Regions. CD44
immunolabeling was only at the unlabeled background level in
Region IV. The level of fluorescence intensity was then about
20-fold higher in Region III, 400-fold higher in Region II, and
800-fold higher in Region I. The difference between Regions I
and II was statistically significant, especially when the data from
saline- and bleomycin-treated mice was pooled (p < 0.002). In
summary, the level of CD44 in both Regions I and II is very high
and is likely to be functionally important in the large population
of Region I cells found in bleomycin lung.
BLOOD FIBROCYTES
To begin to address whether Region I and Region II cells enter
the lung from the circulation already possessing their specialized
phenotype or whether they develop this phenotype in the lung,
we immunolabeled PBMC from mice sacrificed 28 days after
bleomycin treatment for CD45 and Pro (Figure 9A). Essentially
no circulating PBMC show the CD45high phenotype of Region I
cells. Even the few PBMC that fall within Region II are dissimilar
from the lung cells in Region II because the lung cells are
almost completely in the upper half of Region II (in terms
of CD45 level) while the PBMC are almost completely in the
lower half (Figure 9A). These observations strongly support the
notion that the fibrocyte phenotype (exemplified by high levels
of CD45 on Pro+ cells) develops primarily after precursors or
immature fibrocytes enter the lung. This viewpoint is further
supported by preliminary studies (not shown) indicating that 28-
day bleomycin PBMC never exhibit the high levels of HSP47 and
CCR5 found in 28-day bleomycin lung Regions I and II.
To determine whether the accumulation of Region I cells
in bleomycin lung might result from a high level of similar cells
in the circulation at earlier time points, we also quantified cells in
Region I + II in PBMC from saline- and bleomycin-treated mice
3, 10, and 28 days after pump implantation (Figure 9B). While
there were no differences between saline and bleomycin at any
FIGURE 8 | CD44 in Regions I–IV. Total lung cells from saline- and
bleomycin-treated mice sacrificed 28 days after initiation of treatment were
immunolabeled for CD45, Pro, and CD44. CD44 levels in Regions I–IV, and
I + II are shown in terms of the average ± s.e.m. of the median
fluorescence intensity of each of 9 saline and 11 bleomycin mice. S, saline;
B, bleomycin. ∗p < 0.05.
individual time point, there were large differences between the
time points. Just as there were similar high numbers of cells in
Region II in both saline and bleomycin lung at day 3 (Figure 1),
the highest level of circulating Region I+ II cells was at day 3. This
observation strongly suggests that these cells are mobilized from
the bone marrow in response to surgery/pump implantation.
After recovery from surgery, the number of circulating Region
I + II cells is relatively low at days 10 and 28. This decrease
at day 10 is particularly significant when saline and bleomycin
data are pooled (p < 0.002). These observations strongly suggest
either that the cells that comprise bleomycin Region I are either
rapidly recruited from the circulation (and therefore never
accumulate there) or that cells do not differentiate into the
Region I phenotype until after they are recruited into the lung.
FIBROCYTE NUMBER AND FIBROSIS SCORE ARE HIGHLY CORRELATED
We previously demonstrated that the CSD peptide provides
protection against lung fibrosis induced by the delivery of
bleomycin directly into the lungs (Tourkina et al., 2008). As
we have recently demonstrated that the Pump Model, which
involves systemic bleomycin treatment, more closely mimics sev-
eral features of SSc (Lee et al., 2014), here we have determined
whether CSD also provides protection against lung fibrosis in the
Pump Model. In addition, here we did not initiate CSD treat-
ment until 12 days after the initiation of bleomycin treatment,
whereas in our previous study CSD treatment began 1 day prior to
bleomycin treatment (Tourkina et al., 2008). Despite the delayed
treatment, five of nine mice showed noticeable improvement
in tissue morphology and fibrosis score compared to mice that
received bleomycin and CSD vehicle (Figure 10). When fibrosis
score was plotted against fibrocyte number, a striking correla-
tion was observed. For Region I fibrocytes, the correlation was
r = +0.80, p = 0.01; for Regions I + II fibrocytes, the correla-
tion was r = +0.95, p < 0.0001. These results strongly support
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FIGURE 9 | Circulating fibrocytes. (A) PBMC from a bleomycin-treated
mouse sacrificed 28 days after initiation of treatment were immunolabeled
for CD45 and Pro. A scatter plot is presented with CD45 on the y-axis and Pro
on the x-axis showing almost no cells in Region I, few cells in Region II, and
that, even among the few cells present in Region II, almost none were in the
upper half of Region II where almost all lung cells in Region II are located.
This distribution of cells was observed in all PBMC examined from saline- and
bleomycin-treated mice sacrificed 3, 10, or 28 days after the initiation of
treatment. (B) Percent of PBMC in Region I + II in saline- or
bleomycin-treated mice 3, 10, or 28 days after initiation of treatment is
shown. These data represent the average ± s.e.m. for 3 mice in each
category. Sal, saline; Bleo, bleomycin. ∗p < 0.05.
the ideas that fibrocytes play an important role in the progression
of lung fibrosis and that targeting fibrocytes may be an effective
way to treat diseases involving lung fibrosis.
DISCUSSION
Here we have used flow cytometry to study the levels and
immune-phenotype of fibrocytes in the fibrotic lung using
a model system in which bleomycin is delivered systemically
using osmotic minipumps. This Pump Model (Lee et al., 2014)
produces a disease that is muchmore similar to human SSc than is
the more commonmodel in which bleomycin is delivered directly
into the lungs. Our studies also benefited from the use of an
anti-collagen I antibody that we developed against the collagen
Iα1 C-terminal propeptide (referred to as Pro). The key advantage
of this antibody is that the specificity of labeling can be con-
firmed by competition using the immunogenic peptide. Our key
finding is that fibrotic lung fibrocytes can be divided into two
populations: CD45high/Pro+ cells that we refer to as Region I and
CD45+/Pro+ cells that we refer to as Region II. While Region II
fibrocytes are present both in control and fibrotic lung, Region
I fibrocytes are present essentially only in the fibrotic lung. The
remaining cells in the lung can be classified as leucocytes that are
CD45+/Pro- (Region III) and all other cells (CD45-, referred to
as Region IV).
Studies on the time course of appearance of cells in Region I
confirmed the association of these cells with lung fibrosis. These
cells were present at the same low level as in saline-treated, control
mice 3 days after the initiation of bleomycin treatment. Even at
10 days the level in the bleomycin lung was only about 30% of the
level ultimately attained at day 28. Strikingly different results were
attained in Region II in which a large number of cells were present
3 days after the initiation of treatment with either bleomycin or
saline vehicle. This level decreased to near the baseline level at day
10 and remained near this level through day 28, although by this
time the level in the bleomycin lung was slightly (and statistically
significantly) higher in the bleomycin lung. Interestingly, the peak
in number of cells in Region II observed in the lung at day 3
was also observed in the blood at day 3, as was the subsequent
decrease. These observations strongly support the idea that the
increase in cells in Region II observed in both the lung and blood
at day 3 is due to the implantation of pumps and not to the
content of the pumps.
While most experiments in this study were performed with
10-week old male CD1 mice, to confirm that the cells present in
Regions I–III (i.e., all CD45+ cells) are bone marrow-derived,
some experiments were performed with 24-week old C57/BL6
that had been irradiated, then reconstituted with bone marrow
from mice expressing EGFP in all of their cells. Not only did
these studies confirm that Regions I–III cells are all bone marrow-
derived, they confirmed that the existence of Region I cells in
fibrotic mice is not simply an unusual outcome that occurs only
in CD1mice or that occurs only in relatively young mice. It is also
of interest that we observed that the level of EGFP is much higher
in Regions I and II than in Region III (not shown) because the
existence of GFPhigh and GFP+ cells in fibrotic lung has recently
been reported (Nakashima et al., 2013). At present, the relation-
ship between these GFPhigh cells and our GFPhigh cells is a matter
of speculation because our GFPhigh cells are all Pro+ (i.e., Col
I+) while the GFPhigh cells of Nakashima et al. were reported to
be<8% Col I+ (Nakashima et al., 2013).
The central findings of this study regarding the phenotype
of lung fibrocytes and leucocytes are summarized in Table 2. In
accord with the way that Regions I–III were defined, the median
fluorescence intensities of CD45 and Pro were several-fold higher
in saline control fibrocytes than in saline control leucocytes. The
levels of CD45 and Pro immunolabeling were somewhat higher in
fibrotic fibrocytes than in control fibrocytes, presumably because
both CD45 and Pro immunolabeling were at their highest levels
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FIGURE 10 | Correlation between fibrocyte number and fibrosis score.
Mice were treated with saline or bleomycin followed 12 days later by
treatment with CSD or vehicle for 2 weeks. Mice were then sacrificed
on day 26 for histological evaluation and quantification of cells in Regions
I and II. Top: Images are shown for mice treated with Saline (Fibrosis
Score 0), Bleomycin + CSD (Fibrosis Score 2 to 3, 5 of 9 mice
responded in this manner), and Bleomycin + Vehicle (Fibrosis Score 5 to
7). Bottom: For 9 mice receiving Bleomycin + CSD, their Fibrosis Score
is plotted separately vs. percent of total lung cells in Region I and
percent of total lung cells in Regions I + II. For reference, data from
Figure 1D regarding the percent of total lung cells in Region I and
Regions I + II from saline- and bleomycin-treated mice that did not
receive further treatment with CSD or vehicle are presented on the
y-axis as round symbols. Sal, saline; Bleo, bleomycin.
in Region I which is only present in the fibrotic mouse fibrocyte
population. It is also noteworthy that the level of CD45 on
circulating fibrocytes was much less than on lung fibrocytes either
from Region I or Region II.
Results with CXCR4 and CCR5 raise the interesting possibility
that these two chemokine receptors have distinct roles in fibro-
cyte biology. While both are expressed at several-fold higher
levels in saline control fibrocytes than in saline control leuco-
cytes, the increase for CCR5 is three-fold more than for CXCR4.
The levels of both CXCR4 and CCR5 immunolabeling were
somewhat higher in fibrotic fibrocytes than in control fibrocytes
and were at their highest levels in Region I. Interestingly, pre-
liminary studies (not shown) suggest that the level of CXCR4
on lung fibrocytes is little more than the level on circulating
fibrocytes, while the level of CCR5 on lung fibrocytes is much
higher than on circulating fibrocytes. In addition, we show that
the distribution on CD45/Pro scatter plots is different for the
fibrocytes with the highest levels of CCR5 than for the fibro-
cytes with the highest levels of CXCR4, proving that these are
not the same cells. Additional work needs to be done to sort
out the functional significance of these observations and to
determine how CXCR4 and CCR5 may differentially regulate
fibrocyte biology and the role of fibrocytes in fibrosis in various
organs.
The collagen chaperone HSP47 plays critical roles in the
secretion, processing, and formation into fibrils of collagen I
in vitro and in fibrosis in vivo (Ishida et al., 2006; Hagiwara
et al., 2007). We find a huge increase in HSP47 expression in
fibrocytes compared to leucocytes (Table 2). There is a further,
highly significant increase in HSP47 expression in bleomycin
fibrocytes compared to control fibrocytes; however, the level of
HSP47 in bleomycin Region I fibrocytes is not much higher than
in bleomycin Region II fibrocytes. In contrast to all the other pro-
teins examined in this study (CD45, Pro, CXCR4, CCR5, CD44),
there is a population of HSP47high cells that are CD45- (i.e., in
Region IV) that are present at a high level in the bleomycin lung
but not in the control lung. Given that we previously observed
double-positive cells that are Prosurfactant C+/HSP47+ in the
fibrotic, Pump Model lung and in the lungs of SSc patients (Lee
et al., 2014) and that we find that Prosurfactant C+ cells are GFP-
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Table 2 | Phenotypic differences among fibrocytes and between
fibrocytes and leucocytes.
Saline fibrocytes/ Bleomycin fibrocytes/ Bleomycin
saline leucocytes saline fibrocytes region I/bleomycin
region II
CD45 2.9 1.3 2.0
Pro 5.5 1.3 1.6
CXCR4 5.4 1.7* 1.6*
CCR5 14.5 1.2 1.5***
HSP47 14.0 1.7*** 1.2
CD44 28.8 0.8 2.1*
In this table, Leucocytes are defined as cells in Region III and Fibrocytes are
defined as cells in Region I + II. Data are the ratio of median fluorescence
intensity for each pairing from Figures 1, 6–8. *p < 0.05, ***p < 0.002.
in reconstituted mice (not shown), we propose that the many of
the HSP47+ cells in Region IV will be found to be Prosurfactant
C+ cells derived from type II pneumocytes.
Among the proteins examined, the greatest increase we observe
between fibrocytes and leucocytes is in the expression of CD44
(Table 2). This is all the more remarkable because the level in leu-
cocytes (Region III) is much higher still than in CD45- (Region
IV) cells. This is also noteworthy because CD44 and its ligand
hyaluronic acid have been reported to regulate fibrocyte differ-
entiation (Maharjan et al., 2011), although many of the details
remain to be worked out. While the level of CD44 is no higher in
bleomycin fibrocytes than in saline fibrocytes, the level of CD44 is
much higher in bleomycin Region I than in bleomycin Region II.
To address the importance of fibrocytes in lung fibrosis, we
treated mice that received bleomycin via osmotic minipump from
days 0 to 12 with CSD delivered via osmotic minipump from
day 12 to 26. This treatment blocked the migration of bone mar-
row cells isolated from these mice toward several chemokines
including CXCL12, MCP-1, MCP-3, MIP1α, and MIP1β (not
shown) in an in vitro assay, suggesting that the recruitment of
bone marrow-derived cells into affected tissues should be simi-
larly inhibited in vivo. Even though CSD treatment did not begin
until after fibrosis had begun to be established, this treatment
also inhibited both fibrocyte number in the tissue and fibrosis
score with a highly significant correlation. Together, these obser-
vations strongly support the notion that CSD blocks the progres-
sion of fibrosis by blocking the recruitment by chemokines of
bone marrow-derived fibrocytes or their precursors into affected
tissues.
In summary, the results of this study strongly suggest that
fibrocyte differentiation occurs in large part in the target tissue,
in this case the lungs. Besides highlighting fibrocyte recruitment
and differentiation as potential therapeutic targets (using CSD or
other agents) in the treatment of fibrotic diseases, this study also
highlights CD45, CD44, CCR5, CXCR4, and HSP47 as potential
therapeutic targets.
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